Sensei Biotherapeutics (HAM:407) Total Payout Ratio : 0.00 (As of Jun. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Sensei Biotherapeutics's current Total Payout Ratio is 0.00.

Sensei Biotherapeutics Total Payout Ratio Historical Data

The historical data trend for Sensei Biotherapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Total Payout Ratio Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

3.82

-0.30

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sensei Biotherapeutics's Total Payout Ratio

For the Biotechnology subindustry, Sensei Biotherapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensei Biotherapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Total Payout Ratio falls into.

Sensei Biotherapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Sensei Biotherapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-9.522	+	0	+	0)	/	-31.271
	=	-0.30

Sensei Biotherapeutics's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-7.353
	=	0.00

Sensei Biotherapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (HAM:407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

SNSE:USA 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines